Pharmacological reactivation of mutant p53: from protein structure to the cancer patient
β Scribed by Wiman, K G
- Book ID
- 109972383
- Publisher
- Nature Publishing Group
- Year
- 2010
- Tongue
- English
- Weight
- 455 KB
- Volume
- 29
- Category
- Article
- ISSN
- 0950-9232
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Antibodies reacting with the host protein p53 were found in the sera of patients with primary or secondary carcinoma of the breast. Fourteen out of the 155 sera from breast cancer patients tested were positive for antiβp53 antibodies (9%) and no positives were detected among 164 control
Alteration of the p53 gene is thought to be important in the early stages of human esophageal cancers, but how this confers a selective advantage to esophageal cancer cells is unknown. In this report, we analyzed 9 cell lines derived from human esophageal cancers (TE-1, TE-3, TE-6, TE-7, TE-9, TE-10
The p.53 gene and its protein have acquired major importance in the understanding of the origins of neoplasia in human beings. Of all carcinomas, 60-65% contain mutations at thep.53 locus (Levine, 1993) and these mutations take a characteristic form; one p.53 allele usually sustains a point mutation